CELLECTIS SA Receives the INPI Ile-de-France Innovation Award
Paris, December 1, 2009 – Cellectis S.A. (Alternext: ALCLS), the French genome
engineering specialist, has been awarded the Paris Ile-de-France Region SME Innovation
Award by the French Patent and Trademark Office (Institut National de la Propriété
Industrielle, INPI). The company was presented with the award by INPI Chief Executive
Philippe Laval.
The INPI's annual Innovation Awards honor small and medium-sized companies whose success can be attributed to their pro-innovation policies and which use a comprehensive intellectual property (IP) strategy to leverage business growth: economic intelligence, technology watching, IP rights (including patents, trademarks, registered designs and registered models), managing and exploiting license agreements and, last but not least, combating infringement.
“It is essential to link intellectual property rights to the types of public-sector financial support that are available to companies. That is the only way for France to return to the forefront of innovation,” commented Cellectis CEO André Choulika. “Here at Cellectis, our strategy involves building up an IP portfolio which protects our products, their applications and the corresponding body of technological know-how. In fact, this strategy has had (and continues to have) a decisive impact on our business, as Cellectis' rapid growth since its incorporation in 2000 can testify.”
At present, Cellectis holds a portfolio of 42 granted patents and more than 130 pending applications.
About Cellectis S.A.
Cellectis S.A. is a world leader in genome engineering and genome surgery. The company focuses on developing and producing custom meganucleases for use in in vivo genome surgery addressing the therapeutic, agrofood, biomanufacturing and research sectors. Worldwide, Cellectis has entered into more than 50 agreements with major players in the pharma, biotech and agrobiotech industries and has over 20 collaborations with academic research groups. To date, Cellectis has raised over €70 million in both equity operations and public financing and is listed on the NYSE-Euronext Alternext market (ticker code: ALCLS). For more information on Cellectis, visit our website: www.cellectis.com
The INPI's annual Innovation Awards honor small and medium-sized companies whose success can be attributed to their pro-innovation policies and which use a comprehensive intellectual property (IP) strategy to leverage business growth: economic intelligence, technology watching, IP rights (including patents, trademarks, registered designs and registered models), managing and exploiting license agreements and, last but not least, combating infringement.
“It is essential to link intellectual property rights to the types of public-sector financial support that are available to companies. That is the only way for France to return to the forefront of innovation,” commented Cellectis CEO André Choulika. “Here at Cellectis, our strategy involves building up an IP portfolio which protects our products, their applications and the corresponding body of technological know-how. In fact, this strategy has had (and continues to have) a decisive impact on our business, as Cellectis' rapid growth since its incorporation in 2000 can testify.”
At present, Cellectis holds a portfolio of 42 granted patents and more than 130 pending applications.
About Cellectis S.A.
Cellectis S.A. is a world leader in genome engineering and genome surgery. The company focuses on developing and producing custom meganucleases for use in in vivo genome surgery addressing the therapeutic, agrofood, biomanufacturing and research sectors. Worldwide, Cellectis has entered into more than 50 agreements with major players in the pharma, biotech and agrobiotech industries and has over 20 collaborations with academic research groups. To date, Cellectis has raised over €70 million in both equity operations and public financing and is listed on the NYSE-Euronext Alternext market (ticker code: ALCLS). For more information on Cellectis, visit our website: www.cellectis.com